Abstract
Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients. This study aimed to demonstrate the degree of heterogeneity of chemosensitivity in breast cancers. In this study, we examined the heterogeneity of chemosensitivity in breast cancer specimens (n = 50) using an ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Assay evaluability was 92% in surgical biopsies or pleural aspirates. A variety of chemosensitivity agents were tested. We found that the most active single agent tested was paclitaxel, to which 65.9% of samples were sensitive. Combinations of agents also showed more strong sensitivity cases. The Adriamycin+5-FU demonstrated a strong sensitivity in 23 of 43 (52.3%) of samples. Adriamycin+paclitaxel was more effective, with strong sensitivity in 37 of 43 cases tested (86.0%). There was a marked heterogeneity of chemosensitivity in breast cancer. Chemosensitivity testing may provide a practical method of testing new regimens before clinical trials in breast cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bhalla, K. N., Microtubule-targeted anticancer agents and apoptosis. Oncogene, 22, 9075–9086 (2003).
Brown, E. and Markman, M., Tumor chemosensitivity and chemoresistance assays. Cancer, 77, 1020–1025 (1996).
Bull, J. M., Tormey, D. C., Li, S. H., Carbone, P. P., Falkson, G., Blom, J., Perlin, E., and Simon, R., A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer, 41, 1649–1657 (1978).
Buzdar, A. U., Preoperative chemotherapy treatment of breast cancer—a review. Cancer, 110, 2394–2407 (2007).
Chou, T. C. and Talalay, P.,. Quantitative analysis of doseeffect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27–55 (1984).
Di Nicolantonio, F., Knight, L. A., Di Palma, S., Sharma, S., Whitehouse, P. A., Mercer, S. J., Charlton, P. A., Norris, D., and Cree, I. A., Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anticancer Drugs, 15, 849–860 (2004).
Doerler, M., Hyun, J., Venten, I., Potthoff, A., Bartke, U., Serova, K., Hoextermann, S., Altmeyer, P, and Brockmeyer, N. H., Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? A retrospective study of 14 patients with malignant melanoma stage IV. Eur. J. Med. Res., 12, 497–502 (2007).
Gewirtz, D. A., Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res. Treat., 62, 223–235 (2000).
Konecny, G., Crohns, C., Pegram, M., Felber, M., Lude, S., Kurbacher, C., Cree, I. A., Hepp, H., and Untch, M.. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol. Oncol., 77, 258–263 (2000).
Konecny, G., Untch, M., Slamon, D., Beryt, M., Kahlert, S., Felber, M., Langer, E., Lude, S., Hepp, H., and Pegram, M., Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res. Treat., 67, 223–233 (2001).
Kurbacher, C. M., Bruckner, H. W., Cree, I. A., Kurbacher, J. A., Wilhelm, L., Poch, G., Indefrei, D., Mallmann, P., and Andreotti, P. E., Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin. Cancer Res., 3, 1527–1533 (1997).
Kurbacher, C. M. and Cree, I. A., Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol. Med., 110, 101–120 (2005).
Kurbacher, C. M., Cree, I. A., Bruckner, H. W., Brenne, U., Kurbacher, J. A., Muller, K., Ackermann, T., Gilster, T. J., Wilhelm, L. M., Engel, H. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs, 9, 51–57 (1998).
McArthur, H. L. and Hudis, C. A., Advances in adjuvant chemotherapy of early stage breast cancer. Cancer Treat Res., 141, 37–53 (2008).
Mercer, S. J., Somers, S. S., Knight, L. A., Whitehouse, P. A., Sharma, S., Di Nicolantonio, F., Glaysher, S., Toh, S., and Cree, I. A., Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs, 14, 397–403 (2003).
Michalski, C. W., Erkan, M., Sauliunaite, D., Giese, T., Stratmann, R., Sartori, C., Giese, N. A., Friess, H., Kleeff, J., Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br. J. Cancer, 99, 760–767 (2008).
Piccart-Gebhart, M. J. and Sotiriou, C., Adjuvant chemotherapy—yes or no? Prognostic markers in early breast cancer. Ann Oncol (2007).
Whitehouse, P. A., Knight, L. A., Di Nicolantonio, F., Mercer, S. J., Sharma, S., and Cree, I. A., Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs, 14, 369–375 (2003a).
Whitehouse, P. A., Mercer, S. J., Knight, L. A., Di Nicolantonio, F., O’Callaghan, A., and Cree, I. A., Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. Br. J Cancer, 89, 2299–2304 (2003b).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qi, CJ., Ning, YL., Zhu, YL. et al. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay. Arch. Pharm. Res. 32, 1737–1742 (2009). https://doi.org/10.1007/s12272-009-2211-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-2211-0